CLEVELAND, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 pm Eastern. In his presentation, Mr. Petras will provide an update on Sotera Health’s business. Mr. Petras and Jason Peterson, Vice President and Treasurer, will participate in one-on-one meetings with investors during the conference.
Investors and the general public are invited to listen to the live webcast of Mr. Petras’ presentation by accessing the link on the Sotera Health website under the Investor Relations section: https://investors.soterahealth.com/events-and-presentations. A replay and slides for download will also be made available.
About Sotera Health:
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.
INVESTOR RELATIONS CONTACTS: | ||
Jason Peterson Vice President & Treasurer, Sotera Health This email address is being protected from spambots. You need JavaScript enabled to view it. | Sally J. Curley, IRC Curley Global IR, LLC This email address is being protected from spambots. You need JavaScript enabled to view it. | |
MEDIA CONTACT: | ||
Kristin Gibbs Chief Marketing Officer, Sotera Health This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$10.48 |
Daily Change: | -0.01 -0.10 |
Daily Volume: | 834,189 |
Market Cap: | US$2.970B |
March 04, 2025 February 27, 2025 January 14, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load